» Articles » PMID: 35234297

COVID-19 in Pregnancy-what Study Designs Can We Use to Assess the Risk of Congenital Anomalies in Relation to COVID-19 Disease, Treatment and Vaccination?

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The COVID-19 pandemic has accelerated pregnancy outcome research, but little attention has been given specifically to the risk of congenital anomalies (CA) and first trimester exposures.

Objectives: We reviewed the main data sources and study designs used internationally, particularly in Europe, for CA research, and their strengths and limitations for investigating COVID-19 disease, medications and vaccines.

Population: We classify research designs based on four data sources: a) spontaneous adverse event reporting, where study subjects are positive for both exposure and outcome, b) pregnancy exposure registries, where study subjects are positive for exposure, c) congenital anomaly registries, where study subjects are positive for outcome and d) population healthcare data where the entire population of births is included, irrespective of exposure and outcome.

Study Design: Each data source allows different study designs, including case series, exposed pregnancy cohorts (with external comparator), ecological studies, case-control studies and population cohort studies (with internal comparator).

Methods: The quality of data sources for CA studies is reviewed in relation to criteria including diagnostic accuracy of CA data, size of study population, inclusion of terminations of pregnancy for foetal anomaly, inclusion of first trimester COVID-19-related exposures and use of an internal comparator group. Multinational collaboration models are reviewed.

Results: Pregnancy exposure registries have been the main design for COVID-19 pregnancy studies, but lack detail regarding first trimester exposures relevant to CA, or a suitable comparator group. CA registries present opportunities for improving diagnostic accuracy in COVID-19 research, especially when linked to other data sources. Availability of inpatient hospital medication use in population healthcare data is limited. More use of ongoing mother-baby linkage systems would improve research efficiency. Multinational collaboration delivers statistical power.

Conclusions: Challenges and opportunities exist to improve research on CA in relation to the COVID-19 pandemic and future pandemics.

Citing Articles

In need of robust evidence of non-association of pregestational and early pregnancy SARS-CoV-2 infections with congenital anomalies.

Samara A, Souter V, Coutinho C, Khalil A EClinicalMedicine. 2024; 74:102729.

PMID: 39109188 PMC: 11301251. DOI: 10.1016/j.eclinm.2024.102729.


Congenital anomalies in Santa Catarina, Southern Brazil: macroregional and temporal birth prevalence for the period 2011-2020.

Krieck L, Barbian M, Schuler-Faccini L, Pinto Moehlecke Iser B J Community Genet. 2024; 15(4):423-431.

PMID: 38918275 PMC: 11411025. DOI: 10.1007/s12687-024-00716-9.


How Much Does SARS-CoV-2 Infection during Pregnancy Affect the Neonatal Brain, Heart, and Kidney? A Parallel between COVID-19, Vaccination, and Normal Pregnancy.

Popescu D, Jura A, Stiube D, Ciulpan A, Stoica F, Sipos S Life (Basel). 2024; 14(2).

PMID: 38398733 PMC: 10889919. DOI: 10.3390/life14020224.


The COVID-19 Vaccines International Pregnancy Exposure Registry (C-VIPER): Protocol and Methodological Considerations.

Wyszynski D, Bhattacharya M, Martinez-Perez O, Scialli A, Tassinari M, Bar-Zeev N Drug Saf. 2023; 46(3):297-308.

PMID: 36682012 PMC: 9867833. DOI: 10.1007/s40264-022-01271-3.


A population-based matched cohort study of major congenital anomalies following COVID-19 vaccination and SARS-CoV-2 infection.

Calvert C, Carruthers J, Denny C, Donaghy J, Hopcroft L, Hopkins L Nat Commun. 2023; 14(1):107.

PMID: 36609574 PMC: 9821346. DOI: 10.1038/s41467-022-35771-8.


References
1.
Knight M, Bunch K, Vousden N, Morris E, Simpson N, Gale C . Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based cohort study. BMJ. 2020; 369:m2107. PMC: 7277610. DOI: 10.1136/bmj.m2107. View

2.
Wang H, Wender-Ozegowska E, Garne E, Morgan M, Loane M, Morris J . Insulin analogues use in pregnancy among women with pregestational diabetes mellitus and risk of congenital anomaly: a retrospective population-based cohort study. BMJ Open. 2018; 8(2):e014972. PMC: 5855464. DOI: 10.1136/bmjopen-2016-014972. View

3.
Vivanti A, Vauloup-Fellous C, Prevot S, Zupan V, Suffee C, Do Cao J . Transplacental transmission of SARS-CoV-2 infection. Nat Commun. 2020; 11(1):3572. PMC: 7360599. DOI: 10.1038/s41467-020-17436-6. View

4.
Mitchell A . Systematic identification of drugs that cause birth defects--a new opportunity. N Engl J Med. 2003; 349(26):2556-9. DOI: 10.1056/NEJMsb031395. View

5.
Dolk H, Damase-Michel C, Morris J, Loane M . COVID-19 in pregnancy-what study designs can we use to assess the risk of congenital anomalies in relation to COVID-19 disease, treatment and vaccination?. Paediatr Perinat Epidemiol. 2022; 36(4):493-507. PMC: 9115419. DOI: 10.1111/ppe.12840. View